Target Gallery

Upcoming Webinar: The Aptamer, An Alternative to the Antibody for Research and Therapeutic Development

Please join us on Tuesday, May 31st 2016 at 11AM EDT for a webinar led by Dr. Douglas  R. Davies, Sr. Manager of Structural Biology at Beryllium Discovery.

This webinar will highlight unique attributes of SOMAmers but also discuss similarities between aptamers and antibodies from the standpoints of and target protein recognition and shape complementarity.

Register for free here.

Aptamers are nucleic acids that fold into a well-defined three-dimensional structure and exhibit high affinity for a specific target molecule. Many aptamers are simple single-stranded DNA or RNA, although the incorporation of chemical diversity-enhancing side chains has led to the development of “slow off-rate modified aptamers” (SOMAmers). Investigators at Beryllium and SomaLogic, Inc. have collaborated to elucidate three crystal structures of proteins in complex with SOMAmers. The SOMAmer structures are distinctive members of the ensemble of sixteen aptamer-protein complex structures that have been reported to date.

About Beryllium

Beryllium is shaping the future of collaborative drug discovery. Our proven teams of drug discovery professionals are passionate about unlocking the therapeutic potential of both genetically- and clinically-validated drug targets, as well as developing new therapeutic modalities. We work in partnership with our clients to address the most difficult scientific and business challenges facing drug discovery, and to ultimately enable transformational health care outcomes.

We enable novel drug discovery by applying structural and functional biology-centric processes and platforms. Our goal is to deliver validated starting points for drug development programs, and our teams of pharma industry veterans are applying multidisciplinary knowledge to tackle the most promising therapeutic targets.

 

@2016 Beryllium Discovery Corp – 844-BE4-FOUR | info@be4.com

Terms of Services º Terms of Use